Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells
Open accessThe DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
The heterogeneity of cancer cell signaling is a significant obstacle for the effective development and clinical use of molecularly targeted therapies. As a contribution to a better understanding of the diversity of signaling activities in colorectal cancers (CRCs), we have analyzed the activity of Src family kinases (SFKs), which are implicated in human cancer development, in 64 CRC cell lines. A striking diversity of SFK activity was observed within this panel. Importantly, all CRC lines tested depend on SFK activity for their growth. In addition, SFK activity levels strongly correlated with global levels of tyrosine-phosphorylated (pTyr) proteins in CRC lines. SFK inhibition substantially reduced these pTyr levels, suggesting that SFKs may function as signal integration points and master controllers for the pTyr protein status in CRC lines. The majority of analyzed CRC lines with high-SFK activity express activated c-Met (pYpY1234/1235), a receptor tyrosine kinase contributing to the regulation of cell proliferation, migration, and invasion. Inhibition of SFKs reduced c-Met phosphorylation in most cases, indicating a reversed signal flow from SFK to c-Met. We conclude that SFK activity is important for the growth of CRC lines, although only low activity levels are required. If this also is true for CRC patients, tumors with low-SFK activity may be particularly sensitive to SFK inhibitors, and such patients should be targeted in clinical trials testing SFK inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The authors reported that all lines tested depended on SFK activity for growth and concluded from this work SFK activity is important for the growth of CRC lines (Emaduddin et al., 2008).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Emaduddin et al., 2008
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · cited 1×
“Protein concentrations were determined by the Bradford method (31), and Coomassie blue staining of SDS/PAGE-separated proteins was used to further ensure approximately equal loading of samples (SI Fig.”
MethodA genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,602 · cited 1×
“For example, receptor tyrosine kinases such as EGFR, IGF1R, and c-Met (11, 19, 20) have been reported as important SFK activity regulators when ligand-activated, activated by mutations, overexpressed, or transactivated through interactions with other signaling proteins (refs.”
BackgroundThe specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 1×
“To address this issue, 16 CRC lines with either very high- or low-SFK activity were selected and exposed to different doses of PP2, a well characterized SFK inhibitor with a good selectivity profile (17).”
MethodPonzetto, C., Bardelli, A., Zhen, Z., Maina, F., dalla Zonca, P., Giordano, S., Graziani, A., Panayotou, G., & Comoglio, P. M. (1994) · Cell · doi:10.1016/0092-8674(94)90318-2 · Cited by 991 · cited 1×
“The identification of a reversed signal f low from SFK to c-Met is not entirely surprising because c-Met has long been known to form a complex with c-Src (28).”
BackgroundSrc family kinases in tumor progression and metastasis
Summy, J. M., & Gallick, G. E. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023772912750 · Cited by 827 · cited 1×
“Src, the first known and one of the most studied oncogenes, has been implicated in CRC development (8) and poor clinical prognosis (9).”
Backgroundc-Src and cooperating partners in human cancer
Ishizawar, R., & Parsons, S. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.001 · Cited by 617 · cited 2×
“For example, receptor tyrosine kinases such as EGFR, IGF1R, and c-Met (11, 19, 20) have been reported as important SFK activity regulators when ligand-activated, activated by mutations, overexpressed, or transactivated through interactions with other signaling proteins (refs.”
BackgroundMartin, G. S. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35073094 · Cited by 599 · cited 1×
“Martin GS (2001) The hunting of the src. Nat Rev Mol Cell Biol 2:467–475.”
BackgroundMutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers
Wang, Z., Shen, D., Parsons, D. W., Bardelli, A., Sager, J., Szabo, S., Ptak, J., Silliman, N., Peters, B. A., van der Heijden, M. S., et al. (2004) · Science · doi:10.1126/science.1096096 · Cited by 522 · cited 1×
“Suppression of certain phosphatases, either directly or indirectly by mutation or epigenetic changes, also may lead to steady-state activation of SFKs (29).”
BackgroundMutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancer
Smith, G., Carey, F. A., Beattie, J., Wilkie, M. J. V., Lightfoot, T. J., Coxhead, J., Garner, R. C., Steele, R. J. C., & Wolf, C. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122612899 · Cited by 521
Activating SRC mutation in a subset of advanced human colon cancers
Irby, R. B., Mao, W., Coppola, D., Kang, J., Loubeau, J. M., Trudeau, W., Karl, R., Fujita, D. J., Jove, R., & Yeatman, T. J. (1999) · Nature Genetics · doi:10.1038/5971 · Cited by 489 · cited 1×
“Overexpression and hyperactivation of Src, not apparently associated with mutations in the Src gene, appears to be predominant in CRC, although occasional mutations have been reported (10, 11).”
BackgroundHuman colonic adenocarcinoma cells: I. Establishment and description of a new line
Tom, B. H., Rutzky, L. P., Jakstys, M. M., Oyasu, R., Kaye, C. I., & Kahan, B. D. (1976) · In Vitro · doi:10.1007/bf02796440 · Cited by 378
Role of β-arrestin 1 in the metastatic progression of colorectal cancer
Buchanan, F. G., Gorden, D. L., Matta, P., Shi, Q., Matrisian, L. M., & DuBois, R. N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510562103 · Cited by 267
Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines
Liu, Y., & Bodmer, W. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510146103 · Cited by 257
Self-citationActivation of Src kinase in primary colorectal carcinoma: An indicator of poor clinical prognosis
Allgayer, H., Boyd, D. D., Heiss, M. M., Abdalla, E. K., Curley, S. A., & Gallick, G. E. (2002) · Cancer · doi:10.1002/cncr.10221 · Cited by 251 · cited 1×
“Src, the first known and one of the most studied oncogenes, has been implicated in CRC development (8) and poor clinical prognosis (9).”
BackgroundBrowning, M. J., Krausa, P., Rowan, A., Bicknell, D. C., Bodmer, J. G., & Bodmer, W. F. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.7.2842 · Cited by 167
Self-citationYi, T., Bolen, J. B., & Ihle, J. N. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.5.2391 · Cited by 166
Davidson, D., Chow, L. M., Fournel, M., & Veillette, A. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.6.1483 · Cited by 149 · cited 1×
“Furthermore, some SFKs are known or suspected to exist in several splice forms (15, 16), creating an additional layer of complexity.”
BackgroundCritical Evaluation of Current Treatments in Metastatic Colorectal Cancer
Venook, A. (2005) · The Oncologist · doi:10.1634/theoncologist.10-4-250 · Cited by 148
Current and emerging treatment options in chronic myeloid leukemia
Jabbour, E. J., Cortes, J. E., Giles, F. J., O'Brien, S. M., & Kantarjian, H. M. (2007) · Cancer · doi:10.1002/cncr.22661 · Cited by 135 · cited 1×
“In addition to the SFK inhibitor, dasatinib, which is already approved for some advanced forms of chronic myelogenous leukemia (CML) (24), other SFK inhibitors with activity in preclinical animal models are currently being tested in patients.”
BackgroundVeillette, A., Foss, F. M., Sausville, E., Bolen, J. B., & Rosen, N. (1987) · PubMed · Cited by 134
Tyrosine kinase signalling in breast cancer
Hynes, N. E. (2000) · Breast Cancer Research · doi:10.1186/bcr48 · Cited by 128 · cited 1×
“For example, receptor tyrosine kinases such as EGFR, IGF1R, and c-Met (11, 19, 20) have been reported as important SFK activity regulators when ligand-activated, activated by mutations, overexpressed, or transactivated through interactions with other signaling proteins (refs.”
BackgroundWheeler, J., Beck, N. E., Kim, H. C., Tomlinson, I. P. M., Mortensen, N. J. M., & Bodmer, W. F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10296 · Cited by 119
Self-citationc-Yes tyrosine kinase activity in human colon carcinoma.
Park, J., Meisler, A. I., & Cartwright, C. A. (1993) · PubMed · Cited by 108
Cancer genetics: colorectal cancer as a model
Bodmer, W. F. (2006) · Journal of Human Genetics · doi:10.1007/s10038-006-0373-x · Cited by 76
Self-citationMondino, A., Giordano, S., & Comoglio, P. M. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.12.6084 · Cited by 75
The Somatic Evolution of Cancer
Bodmer, W. F. (1997) · Journal of the Royal College of Physicians of London · doi:10.1016/s0035-8819(25)00277-6 · Cited by 50
Self-citationThe somatic evolution of cancer. The Harveian Oration of 1996.
Bodmer, W. F. (1997) · PubMed · Cited by 40
Self-citationSekharam, M., Nasir, A., Kaiser, H. E., & Coppola, D. (2003) · PubMed · Cited by 39
Hirsch, C. L., Smith‐Windsor, E. L., & Bonham, K. (2006) · International Journal of Cancer · doi:10.1002/ijc.21383 · Cited by 26
Herynk, M. H., Zhang, J., Parikh, N. U., & Gallick, G. E. (2007) · PubMed · Cited by 26
Targeted Therapy in Colorectal Cancer
Wadler, S. (2007) · Clinical Colorectal Cancer · doi:10.3816/ccc.2007.n.004 · Cited by 20
Targeted therapy for colorectal cancer.
Hwang, J., & Marshall, J. L. (2006) · PubMed · Cited by 5
Research works printed but not linked: 2
- 10.1128/mcb.11.5.2391-2398.1991 · doi:10.1128/mcb.11.5.2391-2398.1991
- 10.1128/mcb.11.12.6084-6092.1991 · doi:10.1128/mcb.11.12.6084-6092.1991
Cited by
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530
Green, T. P., Fennell, M., Whittaker, R., Curwen, J., Jacobs, V., Allen, J., Logie, A., Hargreaves, J., Hickinson, D. M., Wilkinson, R. W., et al. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2009.01.002 · Cited by 238
“Deregulated elevated Src kinase activity has been reported in a wide range of human tumor types (Frame, 2002; Summy and Gallick, 2003).”
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., & Wheeler, D. L. (2011) · Oncogene · doi:10.1038/onc.2010.430 · Cited by 133
“The authors reported that all lines tested depended on SFK activity for growth and concluded from this work SFK activity is important for the growth of CRC lines (Emaduddin et al., 2008).”
BackgroundPalanikumar, L., Karpauskaite, L., Al-Sayegh, M., Chehade, I., Alam, M., Hassan, S., Maity, D., Ali, L., Kalmouni, M., Hunashal, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23985-1 · Cited by 132
Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis
Chan, C. M., Jing, X., Pike, L. A., Zhou, Q., Lim, D.-J., Sams, S. B., Lund, G. S., Sharma, V., Haugen, B. R., & Schweppe, R. E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3359 · Cited by 111
“The lack of correlation between phospho-SFK levels and sensitivity to dasatinib is similar to our previous studies using the Src inhibitor, saracatinib, as well studies in other tumor types, and suggest that even low levels of SFK activity are sufficient for these biologic responses (23, 44, 45).”
ResultLeroy, C., Fialin, C., Sirvent, A., Simon, V., Urbach, S., Poncet, J., Robert, B., Jouin, P., & Roche, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2354 · Cited by 114
“For instance, Src regulates growth, survival, and invasion of some CRC cell-lines in vitro (3, 5).”
Background
Metadata
- Authors
- Emaduddin, M., Bicknell, D. C., Bodmer, W. F., & Feller, S. M.
- Affiliations
- John Radcliffe Hospital (GB)
- *Cell Signalling Group and
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-02-19
- Volume
- 105
- Issue
- 7
- Pages
- 2358-2362
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2268141
- OpenAlex
- W2038900319
- Cited by
- 50
- References
- 35
- Citations by year
- 2025: 3 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 3 · 2018: 1 · 2017: 4 · 2016: 1 · 2015: 2 · 2014: 3 · 2013: 2 · 2012: 4
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- Src family kinases, colorectal cancer, c-Met phosphorylation, tyrosine phosphorylation, cell proliferation, signal integration, receptor tyrosine kinase, cancer cell lines, targeted therapy
- MeSH terms
- Humans, Colorectal Neoplasms, Phosphotyrosine, src-Family Kinases, Proto-Oncogene Proteins c-met, Cell Line, Tumor, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.